Bank Pictet & Cie Europe AG Sells 6,591 Shares of Moderna, Inc. $MRNA

Bank Pictet & Cie Europe AG decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 47.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,356 shares of the company’s stock after selling 6,591 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Moderna were worth $1,417,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Merck & Co. Inc. bought a new position in shares of Moderna in the second quarter worth about $161,642,545. Louisiana State Employees Retirement System purchased a new position in Moderna in the 1st quarter worth about $899,000. Bank of New York Mellon Corp bought a new stake in Moderna during the 2nd quarter valued at about $119,168,000. Contravisory Investment Management Inc. lifted its holdings in Moderna by 1,387.6% during the 2nd quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock valued at $1,696,000 after buying an additional 22,590 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. purchased a new stake in Moderna in the 2nd quarter valued at about $1,013,000. Institutional investors own 75.33% of the company’s stock.

Insider Transactions at Moderna

In related news, President Stephen Hoge sold 39,145 shares of Moderna stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the transaction, the president directly owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. This trade represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider directly owned 74,129 shares in the company, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 197,251 shares of company stock valued at $33,875,904. Company insiders own 10.80% of the company’s stock.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Investor attention is centered on detailed Phase 3 melanoma data for Moderna’s personalized cancer therapy, expected Saturday. The potential readout is viewed as a major catalyst for the company’s oncology strategy and helped support recent buying interest. What’s Going On With Moderna Stock Monday?
• Positive Sentiment: Oddo BHF raised its Moderna price target to $251 from $170, signaling substantially improved expectations for the company’s pipeline and commercial outlook. Oddo BHF Adjusts Moderna Price Target
• Positive Sentiment: Moderna’s collaboration with Merck is among the oncology programs expected to draw attention at ESMO 2026, keeping investors focused on clinical progress and the potential value of its cancer-vaccine platform. Merck/Moderna and Others to Headline ESMO 2026
• Positive Sentiment: Moderna is being highlighted alongside other healthcare companies benefiting from AI-driven drug development, testing and sequencing trends. This provides additional growth-oriented investor interest, although it is more thematic than tied to near-term financial results. The AI Trade Just Moved Into Your Bloodstream
• Neutral Sentiment: Moderna remains listed among biotech stocks for investors to watch, reflecting continued market interest but not a specific new company catalyst. Top Biotech Stocks to Add to Your Watchlist
• Neutral Sentiment: Coverage of investment-firm views on MRNA indicates ongoing institutional debate over the stock’s valuation, pipeline prospects and risk profile, without a clearly stated new consensus shift. What Are Investment Firms Thinking About Moderna?
• Negative Sentiment: Moderna President Stephen Hoge reported selling shares under a predetermined trading plan. The transaction may be routine, but insider selling can weigh on sentiment, particularly after the stock’s strong run. Stephen Hoge Sells Shares Under Trading Plan
• Negative Sentiment: Separate reports said Moderna’s president sold approximately $8.4 million and $8.6 million of stock. The apparent overlap may represent related reporting of insider transactions, but the sales could reinforce concerns about valuation and executive confidence. Moderna President Sells Stock Insider Selling at Moderna
• Negative Sentiment: A bearish Seeking Alpha analysis argues that investors may be overestimating Moderna’s cancer-vaccine opportunity, highlighting execution, clinical and commercialization risks ahead of definitive data. Moderna: Sell the Cancer Vaccine Hype

Analysts Set New Price Targets

MRNA has been the topic of a number of research analyst reports. JPMorgan Chase & Co. upped their target price on shares of Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research note on Friday, August 21st. Bank of America raised their target price on shares of Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. UBS Group reaffirmed a “neutral” rating on shares of Moderna in a research note on Tuesday, September 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a report on Wednesday, September 9th. Finally, Rothschild & Co Redburn cut Moderna from a “neutral” rating to a “sell” rating and increased their price objective for the stock from $40.00 to $81.00 in a research note on Thursday, September 3rd. Seven analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $101.45.

Moderna Stock Up 5.8%

Shares of MRNA stock traded up $13.07 on Tuesday, hitting $239.96. The stock had a trading volume of 8,637,973 shares, compared to its average volume of 12,354,278. Moderna, Inc. has a one year low of $22.28 and a one year high of $242.29. The business has a 50 day moving average price of $160.00 and a 200 day moving average price of $92.42. The company has a market cap of $95.80 billion, a PE ratio of -29.93 and a beta of 1.09. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.06. The company had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the business earned ($2.13) EPS. Research analysts anticipate that Moderna, Inc. will post -6.11 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.